Robeco Institutional Asset Management B.V. Makes New $267,000 Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Robeco Institutional Asset Management B.V. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 8,151 shares of the specialty pharmaceutical company's stock, valued at approximately $267,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Raiffeisen Bank International AG acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals during the 1st quarter valued at about $30,000. Versant Capital Management Inc grew its stake in shares of Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $42,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares in the last quarter.

Analyst Ratings Changes

Separately, Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, June 21st.

Supernus Pharmaceuticals Stock Down 0.2%

Shares of SUPN stock traded down $0.08 during trading hours on Friday, reaching $32.00. 212,566 shares of the company's stock were exchanged, compared to its average volume of 478,210. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.94 and a fifty-two week high of $40.28. The stock has a market capitalization of $1.79 billion, a P/E ratio of 28.82 and a beta of 0.70. The business has a fifty day moving average price of $32.26 and a 200-day moving average price of $33.85.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.